In the Know: New Treatment Guidelines for Myeloproliferative Neoplasms

As clinicians continue to seek new ways to provide the best patient care for patients with myeloproliferative neoplasms, a group of rare hematological cancers which can be challenging to treat, hear how recent guideline and treatment updates by the National Comprehensive Cancer Network (NCCN) can optimize care for patients with myeloproliferative neoplasms. In this episode, CANCER BUZZ speaks with Andrew Kuykendall, MD, assistant member of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Fla. about the impact of these new guidelines.

“Every single patient is very different in the symptoms they present with, the duration of the disease, and what their goals are in receiving therapy. Ultimately, that often means that we don’t have a one-size-fits-all treatment strategy…Instead, we have a variety of treatment options that can provide different benefits for patients and when you have that, it merely comes down to what makes sense for the patient, what makes sense for the disease, what makes sense for the patient’s family, and what you feel as a physician is the most appropriate for the patient.” – Andrew Kuykendall, MD

This is the fourth video podcast in a four-episode series on myeloproliferative neoplasms in connection with the education program Advancing Care for Patients with Myeloproliferative Neoplasms (MPNs). This episode is supported by Incyte.

Guests: Andrew Kuykendall, MD, 

Assistant Member, Department of Malignant Hematology

Moffitt Cancer Center

Tampa, FL

Resources:

Myeloproliferative Neoplasms (cancersupportcommunity.org)

National Comprehensive Cancer Network (NCCN) Guidelines: Myeloproliferative Neoplasms